LEXINGTON, Mass., June 25, 2018 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology
company devoted to development of next-generation medicines to
improve the lives of patients with immune-mediated diseases, today
announced that the Company was added to the broad-market Russell
3000® Index and the small-cap Russell 2000® Index at the conclusion
of the Russell US Indexes annual reconstitution on June 25th, 2018.
The Russell 3000® Index measures the performance of the largest
3,000 U.S. companies, representing approximately 98% of the
investable U.S. equity market. The Russell 2000® Index measures
performance of the small-cap segment of the U.S. equity market and
is a subset of the Russell 3000® Index, representing approximately
10% of the total market capitalization of the Russell 3000® Index.
Membership in the Russell 2000® Index results in automatic
inclusion in the appropriate growth and style indexes.
Russell Indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $8.5 trillion in assets are benchmarked to or
invested in products based on the Russell U.S. Indexes. Russell
Indexes are provided by FTSE Russell, a leading global index
provider. For more information, visit:
https://www.ftserussell.com/research-insights/russell-reconstitution.
About Aldeyra Therapeutics
Aldeyra
Therapeutics is developing next-generation medicines to improve the
lives of patients with immune-mediated diseases. Aldeyra's lead
product candidate, reproxalap, is a first-in-class treatment in
late-stage development for dry eye disease and other forms of
ocular inflammation. The company is also developing other product
candidates for autoimmune and metabolic diseases. None of Aldeyra's
product candidates have been approved for sale in the U.S. or
elsewhere.
Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 218
dmcmullin@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-joins-the-russell-3000-and-2000-indexes-300671690.html
SOURCE Aldeyra Therapeutics, Inc.